This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Women's Health  • Women's Sexual Function  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2005;165:1571-1572.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the story "Goldilocks and the Three Bears," Goldilocks searches for a bowl of porridge, a chair, and a bed that are "just right." Similarly, Braunstein and colleagues¹ report in this issue of the ARCHIVES their attempt to find the "just right" dose of testosterone for the treatment of surgically menopausal women with hypoactive sexual desire disorder (HSDD) in a well-designed randomized, double-blind, placebo-controlled trial. They report an increase in sexual desire and satisfying sexual activity in a group of surgically menopausal women who received 300 µg daily of a transdermal testosterone preparation for 24 weeks. This is not a surprising outcome given the known effects of this hormone and their previous publication on this subject.² However, while their results add to the growing literature about the use of androgens for HSDD, they also raise many questions about what is the "just right" dose of testosterone.

One of the . . . [Full Text of this Article]

AUTHOR INFORMATION
Robert A. Vigersky, MD

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: A Randomized, Placebo-Controlled Trial
Glenn D. Braunstein, Dale A. Sundwall, Molly Katz, Jan L. Shifren, John E. Buster, James A. Simon, Gloria Bachman, Oscar A. Aguirre, Johna D. Lucas, Cynthia Rodenberg, Akshay Buch, and Nelson B. Watts
Arch Intern Med. 2005;165(14):1582-1589.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Testosterone Therapy on Cardiovascular Risk Markers in Androgen-Deficient Women with Hypopituitarism
Miller et al.
J. Clin. Endocrinol. Metab. 2007;92:2474-2479.
ABSTRACT | FULL TEXT